Tag: Novartis

According to Novartis, the manufacturer of Leqvio, the wholesale acquisition cost for uninsured patients is over $3,500 per dose, creating significant sticker shock for many. This high price tag leaves many patients and healthcare providers asking: why is Leqvio so expensive? The answer lies in a complex interplay of research costs, novel technology, patent protection, and market dynamics.

Following the expiration of the original patent, numerous companies now produce generic versions of imatinib mesylate, a crucial targeted cancer drug. The widespread availability of generic imatinib drugs has significantly changed the market, increasing accessibility and impacting pricing for patients worldwide.

In September 2023, Bausch + Lomb announced the completion of its acquisition of Xiidra from Novartis, a transaction that has prompted many patients to question if the drug is being phased out. The good news is that for patients wondering, 'Is Xiidra being discontinued in the USA?', the answer is no; the medication remains fully available for prescription.

In the United States, over 80% of all prescriptions are filled with a generic medication. However, in the case of **octreotide and Sandostatin**, understanding their relationship is crucial, as one is simply the brand name for the other's active ingredient. This article clarifies the distinction between these two medications and their various formulations.

In 2023, the brand-name diabetes medication Starlix (nateglinide) was officially discontinued in the U.S., following a similar withdrawal from the European market years prior. The definitive reason why was Starlix discontinued, according to its manufacturer, was based on commercial viability and diminishing market demand, not safety issues.

Developed by the Swiss pharmaceutical company Novartis, the groundbreaking biologic Cosentyx, or **secukinumab**, was the first interleukin-17A (IL-17A) inhibitor to receive FDA approval, marking a significant advancement for treating autoimmune and inflammatory diseases. Its development was a long process involving extensive research into inflammatory pathways.

With a reported list price of up to $2.6 million in 2025, Zolgensma therapy is one of the most expensive single-dose treatments in the world. This article explains how much does Zolgensma therapy cost for patients and the healthcare system, exploring the complex factors that influence the final price and outlining available financial assistance.

With a list price of over $2 million per dose, Zolgensma is one of the most expensive medications in the world. This staggering cost raises a critical question for families affected by spinal muscular atrophy (SMA): who pays for Zolgensma? The answer involves a complex combination of health insurance coverage, manufacturer assistance programs, and innovative payment models.

The list price for a single 150mg vial of Ilaris can exceed $20,000 in the US, but the amount a patient ultimately pays varies widely. Understanding how much does Ilaris cost in the US involves looking beyond the high sticker price to navigate a complex system of insurance, dosage requirements, and financial assistance programs.

With an initial price tag exceeding $2.1 million per dose, Zolgensma became known as the world's most expensive medicine upon its approval in 2019. This staggering cost is the result of a complex interplay of factors, including its groundbreaking gene therapy technology, a small patient population, and the innovative pricing strategies employed by pharmaceutical companies.